Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Systematic review and quality assessment of cost-effectiveness analysis of pharmaceutical therapies for advanced colorectal cancer.

Leung HW, Chan AL, Leung MS, Lu CL.

Ann Pharmacother. 2013 Apr;47(4):506-18. doi: 10.1345/aph.1R152. Review.

PMID:
23548649
2.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

3.

Cost effectiveness of fecal DNA screening for colorectal cancer: a systematic review and quality appraisal of the literature.

Skally M, Hanly P, Sharp L.

Appl Health Econ Health Policy. 2013 Jun;11(3):181-92. doi: 10.1007/s40258-013-0010-8. Review.

PMID:
23549792
4.
5.
6.

The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.

Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, Clegg A.

Health Technol Assess. 2010 Mar;14(19):1-204. doi: 10.3310/hta14190. Review.

7.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

8.

Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.

Murray A, Lourenco T, de Verteuil R, Hernandez R, Fraser C, McKinley A, Krukowski Z, Vale L, Grant A.

Health Technol Assess. 2006 Nov;10(45):1-141, iii-iv. Review.

9.

Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review.

Chan AL, Leung HW, Lu CL, Lin SJ.

Ann Pharmacother. 2009 Feb;43(2):296-303. doi: 10.1345/aph.1L504. Review. Erratum in: Ann Pharmacother. 2009 Mar;43(3):551.

PMID:
19193576
10.

Systematic review and quality assessment of economic evaluation studies of injury prevention.

Polinder S, Segui-Gomez M, Toet H, Belt E, Sethi D, Racioppi F, van Beeck EF.

Accid Anal Prev. 2012 Mar;45:211-21. doi: 10.1016/j.aap.2011.07.004. Review.

PMID:
22269503
11.

The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.

Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ.

Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv. doi: 10.3310/hta13410. Review.

12.

Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.

Hedden L, Kennecke H, Villa D, Johnston K, Speers C, Kovacic L, Renouf DJ, Peacock S.

Eur J Cancer. 2012 Sep;48(13):1969-76. doi: 10.1016/j.ejca.2012.01.012.

PMID:
22325838
13.

Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J.

Health Technol Assess. 2012;16(37):1-253, iii-iv. Review.

14.

A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer.

Krol M, Koopman M, Uyl-de Groot C, Punt CJ.

Expert Opin Pharmacother. 2007 Jun;8(9):1313-28. Review.

PMID:
17563265
15.

A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer.

Lange A, Prenzler A, Frank M, Kirstein M, Vogel A, von der Schulenburg JM.

Eur J Cancer. 2014 Jan;50(1):40-9. doi: 10.1016/j.ejca.2013.08.008. Review.

PMID:
24011538
16.
17.

A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.

Jäkel A, Plested M, Dharamshi K, Modha R, Bridge S, Johns A.

Appl Health Econ Health Policy. 2013 Feb;11(1):27-43. doi: 10.1007/s40258-012-0001-1. Review.

PMID:
23329379
18.

When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature.

Talmor D, Shapiro N, Greenberg D, Stone PW, Neumann PJ.

Crit Care Med. 2006 Nov;34(11):2738-47. Review.

PMID:
16957636
19.

The quality of reporting in published cost-utility analyses, 1976-1997.

Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM.

Ann Intern Med. 2000 Jun 20;132(12):964-72.

PMID:
10858180
20.

The safety and effectiveness of different methods of earwax removal: a systematic review and economic evaluation.

Clegg AJ, Loveman E, Gospodarevskaya E, Harris P, Bird A, Bryant J, Scott DA, Davidson P, Little P, Coppin R.

Health Technol Assess. 2010 Jun;14(28):1-192. doi: 10.3310/hta14280. Review.

Items per page

Supplemental Content

Support Center